The World Health Organization on May 17, 2026, declared the Ebola outbreak in the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern (PHEIC), citing 246 suspected cases and 80 deaths in Ituri Province, with confirmed spread to Kinshasa and Kampala [2][9][14]. WHO Director-General Tedros Adhanom Ghebreyesus stated there are "significant uncertainties to the true number of infected persons and geographic spread" [13]. The declaration — the WHO's highest alert level under the International Health Regulations — is intended to mobilize international coordination and resources for a crisis whose full dimensions remain unknown [10][21].

The outbreak is caused by the Bundibugyo species of Ebola virus, first identified in western Uganda in 2007 and responsible for only a handful of recorded outbreaks since [4][5]. Every source in the international coverage identifies the same central vulnerability: the Ervebo vaccine, which helped contain recent Zaire-strain epidemics, is ineffective against Bundibugyo [3][11][16]. Florent Uzzeni, deputy head of emergencies for MSF-Switzerland, stated: « On connaît Ebola, on sait comment l'épidémie peut se comporter, mais en termes de létalité, en termes de traitement, c'est une souche pour laquelle on n'a pas de traitement homologué. Il n'y a pas de vaccin non plus » (We know Ebola, we know how the epidemic can behave, but in terms of lethality, in terms of treatment, this is a strain for which there is no approved treatment. There is no vaccine either) [7]. Infectious disease expert Dr. Céline Gounder noted that different Ebola species require different vaccines and that no Bundibugyo-targeting vaccine is close to deployment [24]. Trudie Lang, a professor at the University of Oxford, described the strain gap as "one of the most significant concerns" [3].

Epidemiologists emphasized that the virus circulated undetected for weeks before the first public alert, which came via social media only after approximately 50 deaths [11][7]. Anne Cori of Imperial College London stated that "ongoing transmission has occurred for several weeks, and the outbreak has been detected very late, which is concerning" [3]. Jean-Jacques Muyembe, co-discoverer of the Ebola virus and head of the DRC's Institut National de Recherche Biomédicale, said: « Personne n'a la maîtrise des chiffres » (Nobody has control of the figures) [7]. Initial GeneXpert diagnostic tests in the field failed due to poor sample quality; confirmation came only after 13 Bundibugyo-positive samples were processed at the INRB laboratory in Kinshasa [7].

Armed conflict in eastern DRC compounds every dimension of the response. The outbreak is centered on gold-mining towns Mongwalu and Rwampara in Ituri Province, where militia activity restricts humanitarian access [23][12]. A confirmed case has now appeared in Goma, a city controlled by the M23 rebel group, creating what French-language coverage described as an epidemic that has crossed a front line [7][17]. Paul Hunter, a professor at the University of East Anglia, reported that health facilities are frequently targeted by armed groups, causing infected individuals to hide in the community rather than seek treatment [11]. Four healthcare workers are among the confirmed dead [7]. The population mobility between mining zones and urban centers further accelerates spread [23][3].

Despite these obstacles, experts noted the DRC's institutional depth. Daniela Manno of the London School of Hygiene & Tropical Medicine said the country's response capacity is "significantly stronger today than it was a decade ago" [3]. Muyembe called for calm, noting the DRC has controlled 15 previous Ebola epidemics without vaccines or treatments, and recommended deploying local personnel rather than teams from Kinshasa to build community trust [7].

The WHO explicitly advised against border closures and travel restrictions, stating that « такие меры обычно принимаются из страха и не имеют под собой научной основы » (such measures are usually taken out of fear and lack scientific basis) [6]. Africa CDC Director Jean Kaseya echoed this position, warning that border closures push people to unmonitored crossing points and worsen rather than contain spread [7]. He urged adherence to funeral safety protocols: "We don't want people infected because of funerals" [13]. Rwanda, however, moved in the opposite direction, closing border crossings with the DRC after the first confirmed case in Goma and announcing tightened screening to "ensure early detection and rapid response if needed" [13][18].

Governments outside Africa sought to reassure domestic populations. German Health Minister Nina Warken assessed the risk to Germany as "äußerst gering" (extremely low) and said no precautions were currently necessary [8]. Vietnam's Ministry of Health advised the public not to panic but recommended 21-day self-monitoring for travelers returning from affected areas [11]. South Korea's Disease Control and Prevention Agency assessed low importation risk but strengthened quarantine measures, including mandatory Q-CODE health declarations for travelers from affected countries [26].

Arabic-language analytical coverage highlighted a structural dimension largely absent from Western reporting: reductions in global health aid — particularly from the United States — have degraded the surveillance and rapid-response capacity that fragile states depend on, making outbreaks harder to detect and contain early [22]. Amanda Rojek of the University of Oxford's Pandemic Sciences Institute said the PHEIC declaration "does reflect that the situation is complex enough to require international coordination" [3].

The WHO stated it would convene an Emergency Committee to recommend temporary measures under the International Health Regulations [10][27]. The US Centers for Disease Control and Prevention announced plans to send additional staff to the DRC and Uganda [13]. Africa CDC reported updated figures of 336 suspected cases and 88 deaths as of May 18, including one death in Uganda [8][20]. No voices from affected communities, patients, or survivors have appeared in international coverage, and no pharmaceutical companies have publicly addressed timelines for a Bundibugyo-specific vaccine.